Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic human insulin 30
Drug: biphasic insulin aspart 30

First Posted Date: 2011-12-07

Last Posted Date: 2017-01-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 170

Registration Number: NCT01487798

Locations: 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom

Bioequivalence of Two Insulatard® Formulations in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: isophane human insulin

First Posted Date: 2011-12-07

Last Posted Date: 2015-04-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT01486901

Special Survey of Production of Insulin Aspart Specific Antibody

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin aspart

First Posted Date: 2011-12-07

Last Posted Date: 2016-03-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 204

Registration Number: NCT01487369

Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2011-12-06

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01486381

Locations: 🇿🇦
Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: insulin

First Posted Date: 2011-12-02

Last Posted Date: 2018-11-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1344

Registration Number: NCT01484262

Locations: 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa pegol

First Posted Date: 2011-11-28

Last Posted Date: 2020-11-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 186

Registration Number: NCT01480180

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

Bioavailability of Three Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women

Phase 1

Completed

Conditions: Menopause
Healthy

Interventions: Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Drug: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)

First Posted Date: 2011-11-22

Last Posted Date: 2016-01-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01477632

Observational Registry of the Treatment of Glanzmann's Thrombasthenia

Completed

Conditions: Congenital Bleeding Disorder
Glanzmann's Disease

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2011-11-22

Last Posted Date: 2014-12-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 218

Registration Number: NCT01476423

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: liraglutide-depot
Drug: placebo

First Posted Date: 2011-11-17

Last Posted Date: 2017-03-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 31

Registration Number: NCT01473953

Locations: 🇺🇸
Novo Nordisk Investigational Site, Evansville, Indiana, United States

A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2011-11-10

Last Posted Date: 2015-02-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01469143

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy